Immuneering Corporation (NasdaqGM: IMRX)
Health Care · Biotechnology · US
$5.23
-1.32% today · -10.9% 1Y
Immuneering Corporation (NasdaqGM: IMRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $342.90M and employs 55 people.
Over the last twelve months the share price has lost 10.9%, trading between 3.86 and 10.08.
Tweenvest scores Immuneering Corporation across four factors: quality 29/100. Its strongest factor is quality.
IMRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $342.90M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.98
- Dividend yield
- —
- Beta (5Y)
- 0.37
- 52-week high
- $10.08
- 52-week low
- $3.86
- Avg volume (3M)
- —
- Shares outstanding
- 64.70M
- Employees
- 55
- Next earnings
- —
About Immuneering Corporation
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
- ISIN
- US45254E1073
- Founded
- 2008
- Listed since
- Jul 30, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.